Search the Newsreel

Why Chennai Petroleum, MRPL shares surged up to 15% today

Occidental Petroleum Corporation $OXY Shares Sold by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab reduced its stake in Occidental Petroleum (OXY) by 41% in the second quarter, selling 25,097 shares and retaining 36,185 shares valued at $1.76 million. Despite this sale, other institutional investors increased their positions, and 88.7% of the stock is owned by institutional …

Finolex Cables stock jumps 12% after Q1 results; profit surges 53% on-year, EBITDA rises 79%

Aldrees Petroleum and Transport Company Powers Ahead, Market Holds Back

FINCABLES: Q1 FY27 revenue up 44% and profit after tax up 59%, with strong cable segment growth

Marathon Petroleum Corporation (MPC) Stock forecasts

Marathon Petroleum Corporation (MPC) is a leading integrated downstream and midstream energy company operating 13 refineries across the U.S. with a significant crude oil refining capacity. The article, based on a Morningstar analyst report, focuses on Marathon Petroleum's earnings and how its operating performance …

Renaissance Technologies LLC Has $2.35 Million Stock Holdings in Imperial Petroleum Inc. $IMPP

Renaissance Technologies LLC significantly increased its stake in Imperial Petroleum Inc. (NASDAQ:IMPP) by 134.3% in the first quarter, now holding 549,140 shares valued at $2.35 million. Other institutional investors also raised their positions, with hedge funds and institutions collectively owning 94.44% of IMPP. Analysts …

First Bank & Trust Sells 1,706 Shares of Costco Wholesale Corporation $COST

Gulf Keystone Petroleum And 2 Other Promising UK Penny Stocks

Assenagon Asset Management S.A. Sells 53,607 Shares of Marathon Petroleum Corporation $MPC

Assenagon Asset Management S.A. reduced its stake in Marathon Petroleum Corporation (NYSE:MPC) by 44.2% in the second quarter, selling 53,607 shares and holding 67,593 shares worth $17.28 million. Despite this, other institutional investors increased their positions, and analysts generally maintain a "Moderate Buy" rating …

100% Return In One Year: Chennai Petroleum Corporation Stock Surges 10% In Trade

IMDX Looks 284.7% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …

Oriole Resources (ORR) Announces High-Grade 28.40g/t Gold at Niambaram and Western CLP Licence Revocation in Cameroon

REG - Oriole Resources PLC - Central Licence Package Update

Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …

METTLER-TOLEDO INTERNATIONAL INC. : MORGAN STANLEY RAISES TARGET PRICE TO $1450 FROM $1275

Morgan Stanley has increased its target price for METTLER-TOLEDO INTERNATIONAL INC. (MTD) shares to $1450 from the previous $1275. This update reflects the investment bank's revised outlook on the company's stock.

Olema Pharmaceuticals falls 6% on second quarter EPS miss

Olema Pharmaceuticals (NASDAQ:OLMA) reported a second-quarter loss of $0.61 per share, missing analyst estimates by $0.06, leading to a 5.8% stock decline. The company's net loss increased to $63.2 million due to higher spending on clinical development for breast cancer therapies palazestrant and OP-3136. …

Olema Pharmaceuticals Q2 Loss Widens

NULL

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

Olema Oncology announced its financial and operating results for the second quarter of 2026, highlighting the completion of enrollment in its pivotal Phase 3 OPERA-01 trial with top-line data expected in Q1 2027. The company also reported initial Phase 1 clinical data for OP-3136, …

Chennai Petroleum Corporation Limited (NSE:CHENNPETRO) Looks Interesting, And It's About To Pay A Dividend

Red Violet earnings beat by $0.17, revenue topped estimates

What Investors Should Know About a Mettler-Toledo Director's Two Transactions This Past Week

A director at Mettler-Toledo International Inc. (MTD), Thomas P. Salice, recently sold 417 shares of the company, valued at approximately $600,651. This transaction was an exercise-and-sell of options, not a change in his long-term investment strategy, as he maintained significant indirect holdings. Mettler-Toledo has …

A Mettler-Toledo Director Sold $600,000 in Stock. Here's What Investors Should Know

A director at Mettler-Toledo International Inc., Thomas P. Salice, sold 415 shares of common stock worth approximately $600,000 after exercising stock options. This transaction, occurring on August 3, was a same-day exercise and sale, where options acquired at a strike price of $397.95 were …

Mettler-Toledo's CFO Cashed In Options After a Strong Quarter. Here's What to Know

Mettler-Toledo International's CFO, Shawn Vadala, sold 2,240 shares for approximately $3.2 million on August 3, 2026, by exercising stock options. This transaction followed a strong quarter for the company, which reported significant revenue growth and raised its full-year outlook. Despite the sale, Vadala retains …

What Investors Should Know as Mettler-Toledo Insiders Sell Shares After a Strong Quarter

Head of Process Analytics Gerry Keller reported a sale of 240 shares of Mettler-Toledo International Inc. (NYSE:MTD) on August 3, following a derivative exercise, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value $342,514 Shares sold (direct) 240 Post-transaction …

Evolent Health, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:EVH) 2026-08-10

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, …

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Red Violet, Inc. Announces $26.7 Million Revenue for Q2 2026 with Strong Earnings Growth

Red Violet, Inc. has announced strong financial results for the second quarter and first half of fiscal year 2026, with revenue reaching $26.7 million. The company filed its quarterly report on Form 10-Q with the SEC, indicating continued revenue growth and positive net income. …

Olema Pharmaceuticals Q2 Results: EPS misses estimates, losses widen

Olema Pharmaceuticals reported a Q2 EPS of $(0.61), missing the analyst consensus of $(0.55) by 10.91%. This represents a 19.61% increase in losses year-over-year from $(0.51), indicating persistent profitability challenges. The company's financial trajectory suggests a disconnect between market expectations and its current performance, …

Occidental Petroleum Corp (OXY) Stock Up 4.9% but GF Value Says Overvalued -- GF Score: 64/100

Occidental Petroleum Corp (OXY) shares rose 4.9% to $58.65, but GuruFocus's GF Value™ indicates it is 18.5% overvalued compared to its estimated fair value of $49.51. Despite a GF Score™ of 64/100 suggesting above-average performance with good financial strength and valuation, the company shows …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss

Olema Pharmaceuticals (OLMA) reported a Q2 loss per share of $0.61, which is wider than the FactSet estimated loss of $0.55 per share. The company is a clinical-stage biopharmaceutical company focused on breast cancer treatments. The article also mentions recent news regarding their clinical …

Red Violet (RDVT) Stock Rises on Q2 2026 Earnings

Red Violet (NASDAQ: RDVT) reported strong Q2 2026 earnings, with revenue, gross profit, operating profit, and net income all showing significant year-over-year increases. Diluted earnings per share exceeded estimates, and operating cash flow improved substantially. Following the announcement, the company's shares rose by 2.5% …

Occidental Petroleum Corp. stock outperforms competitors on strong trading day

Shares of Occidental Petroleum Corp. (OXY) rallied 4.90% to $58.65, outperforming the broader market during a challenging trading session where both the S&P 500 Index and Dow Jones Industrial Average experienced declines. The company's stock closed 13.05% below its 52-week high.

Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS

Olema Pharmaceuticals (NASDAQ:OLMA) reported a quarterly loss of $0.61 per share, missing analysts' consensus estimate by $0.08. The company's stock traded down to $11.94, with a market capitalization of $1.04 billion. Despite missing estimates, Wall Street analysts maintain a "Moderate Buy" consensus rating with …

Insight Molecular Diagnostics: Q2 Earnings Snapshot

The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.